We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ABBV to Boost Immunology Pipeline With Capstan Buyout for $2.1B
Read MoreHide Full Article
Key Takeaways
AbbVie is acquiring Capstan Therapeutics for up to $2.1B to expand its immunology portfolio.
The acquisition adds CPTX2309, a phase I in vivo CAR-T therapy for autoimmune diseases, to AbbVie's pipeline.
Capstan's CellSeeker tLNP platform enables RNA delivery to engineer specific cell types inside the body.
AbbVie (ABBV - Free Report) announced that it has entered into a definitive agreement to acquire privately held biotech, Capstan Therapeutics, for up to $2.1 billion in cash.
The impending acquisition will add Capstan’s lead asset, CPTX2309, a potential first-in-class in vivo tLNP anti-CD19 CAR-T therapy, to AbbiVie’s immunology pipeline. The acquisition will also add Capstan’s proprietary tLNP platform technology, CellSeeker, which helps deliver RNA, like mRNA, to engineer specific cell types inside the body.
CPTX2309 is an in vivo CAR-T therapy using tLNPs to reprogram T cells, aiming to treat autoimmune diseases. The candidate is currently in phase I development for treating B-cell-mediated autoimmune diseases.
The acquisition is subject to customary closing conditions, including regulatory approvals.
Year to date, shares of AbbVie have risen 4.5% against the industry’s decline of 2.6%.
Image Source: Zacks Investment Research
AbbVie on an Acquisition Spree
AbbVie has been on an acquisition spree lately, which is strengthening its pipeline. Particularly, it is signing several M&A deals in the immunology space, its core area, while also signing some early-stage deals in oncology and neuroscience areas.
It has signed more than 20 early-stage deals since the beginning of 2024, including promising technologies and innovative mechanisms that can elevate the standard of care in immunology, oncology and neuroscience.
Earlier this year, AbbVie bought rights to develop GUB014295 (ABBV-295), a long-acting amylin analog for the treatment of obesity, from Denmark’s Gubra. The deal marked AbbVie’s entry into the lucrative obesity space.
In January 2025, AbbVie completed the acquisition of Nimble Therapeutics. The acquisition added Nimble’s lead asset, an investigational oral peptide IL23R inhibitor currently in preclinical development for the treatment of psoriasis. The acquisition also allows AbbVie to utilize Nimble's proprietary peptide synthesis platform to enable the discovery and optimization of oral peptide therapeutics for autoimmune diseases.
In the past 60 days, estimates for Exelixis’ earnings per share have increased from $2.31 to $2.64 for 2025. During the same time, earnings per share estimates for 2026 have increased from $2.85 to $3.13. Year to date, shares of EXEL have rallied 32.4%.
EXEL’s earnings beat estimates in each of the trailing four quarters, the average surprise being 48.60%.
In the past 60 days, estimates for Spero Therapeutics’ loss per share have narrowed from $2.32 to $1.43 for 2025. During the same time, loss per share estimates for 2026 have narrowed from $1.98 to $1.15. Year to date, shares of SPRO have surged 181.5%.
SPRO’s earnings beat estimates in two of the trailing four quarters, while missing the same in the remaining two occasions, the average surprise being 8.29%.
In the past 60 days, estimates for Puma Biotechnology’s earnings per share have increased from 60 cents to 65 cents for 2025. During the same time, earnings per share estimates for 2026 have risen from 46 cents to 51 cents. Year to date, shares of PBYI have gained 12.5%.
PBYI’s earnings beat estimates in each of the trailing four quarters, the average surprise being 171.43%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
ABBV to Boost Immunology Pipeline With Capstan Buyout for $2.1B
Key Takeaways
AbbVie (ABBV - Free Report) announced that it has entered into a definitive agreement to acquire privately held biotech, Capstan Therapeutics, for up to $2.1 billion in cash.
The impending acquisition will add Capstan’s lead asset, CPTX2309, a potential first-in-class in vivo tLNP anti-CD19 CAR-T therapy, to AbbiVie’s immunology pipeline. The acquisition will also add Capstan’s proprietary tLNP platform technology, CellSeeker, which helps deliver RNA, like mRNA, to engineer specific cell types inside the body.
CPTX2309 is an in vivo CAR-T therapy using tLNPs to reprogram T cells, aiming to treat autoimmune diseases. The candidate is currently in phase I development for treating B-cell-mediated autoimmune diseases.
The acquisition is subject to customary closing conditions, including regulatory approvals.
Year to date, shares of AbbVie have risen 4.5% against the industry’s decline of 2.6%.
Image Source: Zacks Investment Research
AbbVie on an Acquisition Spree
AbbVie has been on an acquisition spree lately, which is strengthening its pipeline. Particularly, it is signing several M&A deals in the immunology space, its core area, while also signing some early-stage deals in oncology and neuroscience areas.
It has signed more than 20 early-stage deals since the beginning of 2024, including promising technologies and innovative mechanisms that can elevate the standard of care in immunology, oncology and neuroscience.
Earlier this year, AbbVie bought rights to develop GUB014295 (ABBV-295), a long-acting amylin analog for the treatment of obesity, from Denmark’s Gubra. The deal marked AbbVie’s entry into the lucrative obesity space.
In January 2025, AbbVie completed the acquisition of Nimble Therapeutics. The acquisition added Nimble’s lead asset, an investigational oral peptide IL23R inhibitor currently in preclinical development for the treatment of psoriasis. The acquisition also allows AbbVie to utilize Nimble's proprietary peptide synthesis platform to enable the discovery and optimization of oral peptide therapeutics for autoimmune diseases.
ABBV's Zacks Rank & Stocks to Consider
AbbVie currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Exelixis (EXEL - Free Report) , Spero Therapeutics (SPRO - Free Report) and Puma Biotechnology (PBYI - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 60 days, estimates for Exelixis’ earnings per share have increased from $2.31 to $2.64 for 2025. During the same time, earnings per share estimates for 2026 have increased from $2.85 to $3.13. Year to date, shares of EXEL have rallied 32.4%.
EXEL’s earnings beat estimates in each of the trailing four quarters, the average surprise being 48.60%.
In the past 60 days, estimates for Spero Therapeutics’ loss per share have narrowed from $2.32 to $1.43 for 2025. During the same time, loss per share estimates for 2026 have narrowed from $1.98 to $1.15. Year to date, shares of SPRO have surged 181.5%.
SPRO’s earnings beat estimates in two of the trailing four quarters, while missing the same in the remaining two occasions, the average surprise being 8.29%.
In the past 60 days, estimates for Puma Biotechnology’s earnings per share have increased from 60 cents to 65 cents for 2025. During the same time, earnings per share estimates for 2026 have risen from 46 cents to 51 cents. Year to date, shares of PBYI have gained 12.5%.
PBYI’s earnings beat estimates in each of the trailing four quarters, the average surprise being 171.43%.